- Trevena has been on my watch list for a few years, but my buy conditions were never aligned. Now, I am looking to start a small position in TRVN.
- The company's flagship product, OLINVYK, was launched back in January of this year. I don't expect the company to report impressive numbers considering the pandemic's impact on elective surgeries.
- Trevena has a strong list of upcoming catalysts that should inject some momentum into the ticker until OLINVYK gets some grip in the market.
- I plan on having a systematic approach to accumulating sizeable TRVN position over the remainder of 2021. I discuss my system and plans for TRVN.
For further details see:
Trevena: Taking A Systematic Approach With A Speculative Investment